A federal judge in Delaware on Friday ruled in favor of the Biden administration in a case brought by AstraZeneca seeking to overturn parts of the drug price negotiations established by the Inflation Reduction Act.
The opinion makes clear that AstraZeneca’s constitutional challenge against the IRA should not move forward because the company “has no legitimate claim of entitlement to sell its drugs to the Government at any price other than what the Government is willing to pay,” meaning “its due process claim fails as a matter of law.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.